Benzinga | Aug 19, 2020 10:16AM EDT

Wells Fargo Downgrades Momenta Pharmaceuticals to Equal-Weight, Raises Price Target to $52.5

Wells Fargo analyst Yanan Zhu downgrades Momenta Pharmaceuticals (NASDAQ:MNTA) from Overweight to Equal-Weight and raises the price target from $48 to $52.5.